Lee, C.K., Brown, C., Gralla, R.J., Hirsh, V., Thongprasert, S., Tsai, C.M., Tan, E.H., Ho, J.C., Chu, D.T., Zaatar, A., Osorio Sanchez, J.A., Vu, V.V., Au, J.S., Inoue, A., Lee, S.M., Gebski, V. and Yang, J.C. (2013) Impact of EGFR Inhibitor in Non-Small Cell Lung Cancer on Progression-Free and Overall Survival: A Meta-Analysis. Journal of the National Cancer Institute, 105, 595-605.
http://dx.doi.org/10.1093/jnci/djt072

has been cited by the following article:

• TITLE: Five-Year Survivors of Non-Small Cell Lung Cancer Patients with Positive Pleural Lavage Cytology

  AUTHORS: Masaki Tomita, Takanori Ayabe, Eiichi Chosa, Kunihide Nakamura

  KEYWORDS: Pleural Lavage Cytology Positive; Non-Small Cell Lung Cancer; 5-Year Survivor

  JOURNAL NAME: Advances in Lung Cancer, Vol.3 No.1, February 24, 2014

  ABSTRACT: Background: The pleural lavage cytology (PLC) for non-small cell lung cancer (NSCLC) patients has been reported as a significant prognostic factor. The aim of this study is to clarify the clinicopathological characteristics of 5-year survivors of patients with positive PLC. Methods: Among 401 resected NSCLC patients, 30 (7.48%) patients with positive PLC were reviewed retrospectively. Results: Only 7 of 30 patients (23.3%) survived more than 5-year. There were no differences in age, gender, histology, pT status and pN status between 5-year survivors and non-survivors. On the other hand, the serum carcinoembryonic antigen (CEA) level was significantly higher in non-survivors. Among these 5-year survivors, 4 of 7 patients died of NSCLC recurrences more than 5 years after surgery. Remaining 3 patients survived without cancer recurrences. Interestingly these 3 survivors had not received any adjuvant therapies after surgery. Conclusion: None of the 5-year survivor with positive PLC had high serum CEA level. Furthermore 5-year survival did not equal to cure in NSCLC patients with positive PLC.